The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial. On November 21, 2025, the FDA approved pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph ...

The KEYNOTE-905 trial showed significant survival benefits with enfortumab vedotin and pembrolizumab in muscle-invasive bladder cancer, suggesting a new standard for cisplatin-ineligible patients. The ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

Experts discuss the ways in which AI could transform patient care and improve physician workflows, particularly for benign prostatic hyperplasia.

The phase 3 trial AB22007 will assess masitinib with docetaxel in mCRPC, using a biomarker for patient selection. The trial aims to enroll 600 patients, focusing on radiographic progression-free ...

The TOBY Test uses AI and gas chromatography–mass spectrometry to analyze urine for early cancer detection, offering a significant advantage over current methods. The FDA's breakthrough device ...

The investigators assessed EFS data from the CREST trial based on subgroups stratified by disease stage. Topline data from the phase 3 CREST trial (NCT04165317) showed that the investigational ...

“The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer," says Laura E. Davis, MD.

Experts share their initial impressions of the available data on immunotherapies, including PD-L1 inhibitors durvalumab and sasanlimab, being evaluated in bacille Calmette-Guérin (BCG)–unresponsive ...

The Visby Medical test is the first at-home, prescription-free diagnostic for chlamydia, gonorrhea, and trichomoniasis. It provides results in approximately 30 minutes using a self-collected vaginal ...

Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize ...

Kidney stone prevalence in US adults is stable, but significantly increased among women, especially those under 60. Obesity, metabolic syndrome, and improved healthcare access may contribute to the ...